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ABSTRACT
Cardiovascular diseases are the most prominent circulation disorders around the world. Biomarkers are 
characteristic biological properties that can be objectively measured as an indicator to evaluate a variety of health 
or disease characteristics. Cardiac biomarkers are a valuable tool for assessing the pathogenesis and diagnosis 
of cardiovascular diseases. In this review, we will focus on the major biomarkers used in recent clinical research 
for the diagnosis of cardiovascular diseases, which include mean platelet volume, hyperhomocysteinemia, 
serum magnesium, microalbuminuria, and prolongation of QT interval and dispersion. We also highlight the 
key findings of clinical case report based studies presented in this issue of JCDR.
Key words: Biomarkers, cardiovascular  diseases, pathogenesis
A brief review of biomarkers for preventing  and treating  
cardiovascular diseases
Xiaolun Sun, Zhenquan Jia1
Department of Medicine, University of North Carolina, Chapel Hill, 1Department of Biology, University of 
North Carolina at Greensboro, Greensboro, North Carolina, USA
Address for correspondence: Dr. ZhenquanJia, University of North Carolina at Greensboro, 321 McIver 
Street, 312 Eberhart Building, Greensboro,North Carolina 27412, USA. E-mail: z_jia@uncg.edu
JCDR
pleased to present a review, four clinical case report-based 
studies and ten clinical/translational research articles that 
are relevant to use of  biomarkers for early prevention and 
therapeutic targets. In this review, we will discuss these 
major biomarkers and highlight recent clinical case report 
based studies. JCDR is dedicated to publishing recent 
clinical case report based studies and up-to-date biomarkers 
in clinical and basic cardiovascular research, and welcomes 
submissions that add to our growing body of  knowledge 
on the pathogenesis of  cardiovascular disease.
Cardiovascular diseases are usually diagnosed in middle-
aged or elderly individuals regardless of  gender. The 
underlying pathogenesis of  cardiovascular diseases is 
atherosclerosis. The leading pathological process of  
atherosclerosis, however, begins asymptomatically early 
in life and progresses gradually through adolescence and 
early adulthood.[2,3] Despite continuous improvement in 
preventing and treating cardiovascular diseases, subclinical 
atherosclerosis in an asymptomatic population has long 
been overlooked. This leads to the loss of  critical windows 
for prevention and to long-term delay between the initial 
development of  atherosclerosis in young individuals and 
Edi tor ia l  Review
Cardiovascular diseases are heterogeneous circulation 
disorders that include rheumatic, hypertensive, ischemic, 
cerebrovascular, and inflammatory heart diseases, based 
on the World Health Organization’s classification. In 
2008, there were an estimated 57 million global deaths, of  
which 30.5% were attributed tocardiovascular disease.[1] 
This fraction is greater than the proportion of  combined 
deaths stemming from other diseases such as malignant 
neoplasms, other neoplasms, diabetes mellitus, nutritional/
endocrine disorders, respiratory diseases, and digestive 
diseases. Death from cardiovascular diseases is preventable 
with accurate early-stage diagnosis and subsequent proper 
treatment. Correct diagnosis is dependent upon cardiac 
biomarkers, the focus of  this issue of  JCDR. We are 
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the sudden and fatal manifestation of  heart disease several 
decades later. Therefore, it becomes urgent to identify 
reliable risk factors/biomarkers forprevention, early 
detection and treatment of  the diseases. Histopathological 
and biological alterations during atherosclerosis have been 
utilized to provide insight into cardiovascular disease 
progression. Dr. Thej and colleagues at Sri Devaraj 
Urs Medical College uncovered histomorphological 
atherosclerotic alterations in 113 deceased individuals 
whose ages ranged from 8 to 85 years old.[4] They observed 
an alarming trend of  increased death with intermediate 
lesions in young individuals of  15–34 years old. Their 
study also revealed that males are twice more likely to 
die from cardiovascular disease as compared to females. 
Interestingly, the artery location is associated with onset 
of  atherosclerosis. For instance, atherosclerotic lesions at 
the left anterior descending artery were more frequently 
observed compared to other coronary arteries. This report 
highlights the importance of  diagnosing early onset of  
cardiovascular diseases for prevention and treatment, 
especially in asymptomatic individuals.
Much data have accumulated to support the use of  certain 
risk factors and biomarkers as valuable tools for preventing 
and treating cardiovascular diseases. In the second original 
clinical research article, Dr. Vitthal et al. at SDM College 
of  Medical Sciences in India identified mean platelet 
volume (MPV) as a reliable biomarker for cardiovascular 
diseases.[5] They reported that patients suffering from acute 
myocardial infarction (MI, 39 subjects) and stable coronary 
artery diseases (CAD, 24 subjects) displayed higher MPVas 
compared to 65 healthy controls. They concluded that 
elevated MPV can be used as a biomarker for monitoring 
risk of  acute MI and CAD. Consistently, previous studies 
reported that increased MPV was associated with risk 
for cardiovascular disease in the elderly population.[6] 
Importantly, an increased MPV also indicates a poor 
outcome among survivors of  MI[7] suggesting that MPV 
may be a potential therapeutic target.[8,9]
Homocysteine, a homologue of  cysteine, is synthesized 
from methionine by removal of  its terminal Cε methyl 
group. It was suggested to be a modest independent 
predictor of  coronary heart disease.[10,11] Dr. Naghshtabrizi 
and coworkers at Hamedan Medical University in Iran 
found an association between cardiovascular disease and 
elevated serum homocysteine or the homozygous C677T 
mutation in methylene tetrahydrofolate reductase,[12] a 
gene that encodes an important enzyme in homocysteine 
metabolism. Increased plasma homocysteine results from 
multiple factors, such as vitamin deficiencies (B6, B9, and 
B12), renal impairment, and gene polymorphisms. However, 
it remains debatable whether lowering homocysteine 
through supplementing vitamin B6, B9, and B12 prevents 
cardiovascular disease.[13,14]
Serum magnesium is another biomarker for cardiovascular 
disease, according to areport from Dr. Mahalle’s group at 
Deenanath Mangeshkar Hospital and Research Center 
in India.[15] They detected elevated total cholesterol, 
triglycerides, very low-density lipoprotein (VLDL) and 
LDL and reduced high DL cholesterol in subjects with 
lower serum magnesium (<1.6 mg/dl) and CAD compared 
to controls. Diabetes, dyslipidemia, and hypertension 
were negatively correlated with serum magnesium levels. 
Furthermore, dietary magnesium was positively correlated 
with serum magnesium. The authors concluded that 
hypomagnesaemia and low dietary magnesium in CAD 
patients are strong risk factors. Magnesium behaves like a 
natural calcium channel blocker to attenuate blood pressure 
and blood pressure-induced CAD.[16,17] Supplementing 
dietary magnesium may improve hypertension and CAD.
Microalbuminuria (MA) is a persistent, increased urinary 
excretion of  albumin,[18] and based on the findings of  Dr. 
Goud and colleagues at RAK Medical & Health Sciences 
University in United Arab Emirates,[19] may also be a 
candidate biomarker for cardiovascular disease risk. They 
found increased circulating levels of  MA, high-sensitivity 
C-reactive protein (hsCRP), and LDL cholesterol in 
MI patients as compared to healthy individuals. The 
authors concluded that MA and hsCRP evaluation may 
improve cardiovascular risk prediction when combined 
with traditional lipid profiles. Similarly, other researchers 
reported that MA also correlates with various cardiac 
abnormalities and diseases, such as left ventricular 
dysfunction and hypertrophy, electrocardiographic 
abnormalities, and ischemic heart disease.[20] Strategies to 
reduce MA are recommended to delay progression of  
cardiovascular diseases. Perhaps the most important and 
efficient approach is the reduction of  blood pressure. 
Angiotensin receptor blocker used alone or in conjunction 
with an ACE inhibitor may facilitate a reduction in MA.[21] 
Thiazide diuretics function to decrease proteinuria,[22] and 
dietary salt restriction may also promote reduction of  
urinary albumin excretion.[23]
Dr. Akintunde and colleagues at Ladoke Akintola University 
of  Technology in Nigeria reported that QT interval and 
dispersion may be a risk factor for hypertension.[24] QTmax, 
QTcmax, QTd, and QTcd were higher in hypertensive 
subjects compared to controls. QTc dispersion was 36.4% 
greater in hypertensive subjects. Hypertensive subjects with 
aberrant QT had higher mean waist hip ratio, mean body 
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mass index, and higher prevalence of  smoking compared 
to controls. Moreover, QT prolongation and increased 
QTc dispersion are common among newly diagnosed 
hypertensive individuals. The authors concluded that 
therapies targeting both hypertension and obesity are 
important for newly diagnosed hypertensive patients. 
Studies have demonstrated the relationship between 
mortality and prolonged QT interval and increased 
QT interval dispersion in cardiovascular diseases.[25] 
Prolongation of  the QT interval or QTc may reflect the 
presence of  ischemic heart diseases,[26] and increased QT 
interval dispersion may mirror discrepant repolarization 
characteristics of  different areas of  the heart.[27]
Hypertension is associated with obesity or metabolic 
syndrome. Dr. Lemboa’s group at National University of  
Cuyo in Argentina investigated vascular impairment in 
metabolic syndrome using a rat model.[28] They chronically 
administrated fructose to spontaneously hypertensive rats 
(FFHR) to generate impairment in vascular repairing by 
endothelial progenitor cells (EPC). Decreased proliferation 
of  EPC and colony forming units were found in both 
fructose-treated FFHR (SHR fructose feed rats) and FFR 
(WKY fructose feed rats) compared to untreated controls. 
The fructose-fed groups also showed increased apoptotic 
(annexinV+/7AADdim) EPC, which was reversed after 
fructose feeding was terminated. The authors suggested 
that increased EPC apoptosis could lead to impaired 
vascular repair.
Rhabdomyolysis is an uncommon but life-threatening 
adverse effect of  simvastatin therapy. Dr. Alreja and 
coworkers at School of  Medicine at Tufts University 
in MA in the United States reported a clinical case of  
rhabdomyolysis in a 73-year-old male caused by an 
unusual interaction between azithromycin and simvastatin.
[29] The patient presented with weakness of  extremities 
and a significant increase in creatinine phosphokinase 
levels and acute kidney injury. Simvastatin therapy was 
concluded and supportive therapy with intravenous saline 
and bicarbonate was initiated. The serum creatinine and 
creatine phosphokinase returned to baseline over the next 
7 days. Two months later, simvastatin was resumed without 
any recurrence of  symptoms.
Dr. Patra and colleagues at Department of  Cardiology at Sri 
Jayadeva Institute of  Cardiovascular Sciences and Research 
in India presented a clinical case report based study of  a 
patient of  Ebstein’s anomaly associated with biventricular 
noncompaction presented with Wolf  Parkinson White 
syndrome (WPWS).[30] A 34-year-old male patient presented 
with recurrent attack of  palpitation and chest pain due to 
WPWS. Two-dimensional echocardiography demonstrated 
features of  Ebstein’s anomaly along with biventricular 
noncompaction. Color flow Doppler studies confirmed 
the presence of  blood flow within the trabeculations. 
Biventricular myocardial noncompaction associated with 
Ebstein’s anomaly, presented with WPWS is a very rare 
association. The patient was treated with radiofrequency 
ablation of  right sided posteroseptal accessory pathway 
of  WPWS and was asymptomatic in further follow-up.
Dilated cardiomyopathy (DCM) is the third most common 
cause of  heart failure and the most frequent cause of  heart 
transplantation with an estimated prevalence of  1:2500. 
Dr. Seemann and coworkers at Henri Mondor Hospital 
in France presented a clinical case report based study of  
severe dilated cardiomyopathy with left ventricular apical 
thrombus in a 48-year-old patient.[31] The patient’s medical 
history included diabetes mellitus and hypertension. In this 
case, the authors further discussed the criteria for diagnosis 
and therapy.
In summary, this editorial review provides a concise 
overview of  the diverse array of  reportsin the current 
issue that encompass the use ofbiomarkers for preventing 
and treating cardiovascular diseases. Lastly, we would like 
to express our sincere appreciation to the authors for their 
contribution and to reviewers and editorial staff  for their 
dedication and hard work, propelling the JCDR into one of  
the most prestigious journals in the field of  cardiovascular 
research.
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